Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/1997

01-07-1997

An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer

Authors: Michael Crump, Carol A. Sawka, Gerrit DeBoer, Roger B. Buchanan, James N. Ingle, John Forbes, J. William Meakin, Wendy Shelley, Kathleen I. Pritchard

Published in: Breast Cancer Research and Treatment | Issue 3/1997

Login to get access
Metadata
Title
An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer
Authors
Michael Crump
Carol A. Sawka
Gerrit DeBoer
Roger B. Buchanan
James N. Ingle
John Forbes
J. William Meakin
Wendy Shelley
Kathleen I. Pritchard
Publication date
01-07-1997
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 3/1997
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1005833811584

Other articles of this Issue 3/1997

Breast Cancer Research and Treatment 3/1997 Go to the issue

OriginalPaper

Expression of the prolactin gene in normal and neoplastic human breast tissues and human mammary cell lines: Promoter usage and alternative mRNA splicing

OriginalPaper

Risk factors for breast cancer: A case-control study of screen-detected breast cancer in Miyagi Prefecture, Japan

OriginalPaper

Breast conserving therapy in stage I & II breast cancer in Korea

OriginalPaper

Associations of alcohol, height, and reproductive factors with serum hormone concentrations in postmenopausal Japanese women

BriefCommunication

Brca2 hereditary breast cancer pathophenotype

OriginalPaper

Changes of biological features in breast cancer cells determined by primary chemotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits